New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:04 EDTTTEK, TOT, MXWL, AGN, WBK, RENT, SSW, ESI, IBM, STO, PXD, FRXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Buy from Neutral at SunTrust... American Express (AXP) upgraded to Positive from Neutral at Susquehanna ... Forest Labs (FRX) upgraded to Outperform from Neutral at Credit Suisse... ITT Educational (ESI) upgraded to Buy from Neutral at BofA/Merrill... Maxwell (MXWL) upgraded to Overweight from Neutral at Piper Jaffray... Pioneer Natural (PXD) upgraded to Buy from Hold at Stifel... Seaspan (SSW) upgraded to Hold from Sell at Stifel... Statoil (STO) upgraded to Buy from Hold at Deutsche Bank... Total (TOT) upgraded to Buy from Neutral at Citigroup... Rentrak (RENT) upgraded to Market Perform from Underweight at Albert Fried... IBM (IBM) upgraded to Buy from Outperform at CLSA... Tetra Tech (TTEK) upgraded to Overweight from Equal Weight at Stephens... Westpac Banking (WBK) upgraded to Neutral from Sell at Goldman.
News For AGN;FRX;ESI;MXWL;PXD;SSW;TOT;STO;RENT;TTEK;IBM;WBK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
10:50 EDTAGNBofA names Pfizer a top pick with limited downside, significant upside
Bank of America Merrill Lynch named Pfizer (PFE) as a top pick for 2016 and added the stock to its US 1 list, saying the pharmaceutical giant's stock is "defensive," yet also has the potential to rise significantly. BULLISH VIEW: There's a very good chance that Pfizer will "vastly" exceed earnings per share expectations going forward, due to the large share buybacks that the company can carry out, Bank of America analyst Colin Bristow believes. The pharmaceutical giant's $36B in cash and equivalents, along with its strong cash flow, can facilitate huge share repurchases, he contends. Moreover, Pfizer's acquisition of Allergan (AGN) increases the value of Pfizer's shares by $4 and should increase its EPS by about 17% in 2019, Bristow stated. After Pfizer's stock fell 25% in the wake of its Allergan deal, the shares have reached a "floor value," and can rise about 51%, assuming the Allergan deal closes, Bristow believes. If the Allergan deal falls through, Pfizer's stock will get "some downside protection" in the short-term, while the shares can still rise 37% over the longer term, the analyst stated. Additionally, Pfizer's 4% dividend yield, high quality earnings and high liquidity levels should be appealing to investors, given the market's current turbulence, according to Bristow, who kept a $39 price target and Buy rating on the shares. PRICE ACTION: In morning trading, Pfizer shares slipped fractionally to $28.52.
08:08 EDTIBMIBM Consolidated selected by Edison companies as provider
Subscribe for More Information
February 8, 2016
18:08 EDTESIEducation Department creates enforcement unit targeting education institutions
Subscribe for More Information
13:28 EDTTOTTotal starts up production at Laggan-Tormore in west of Shetland area
Subscribe for More Information
09:34 EDTAGNPfizer sees decision about potential separation by no later than end 2018
Subscribe for More Information
09:32 EDTAGNPfizer names executive leadership team for combined organization
Subscribe for More Information
07:37 EDTAGNSupernus prevails in Oxtellar XR ANDA litigation
Subscribe for More Information
February 5, 2016
15:03 EDTAGNCourt rules in favor of Supernus on two patents in suit with Actavis
The U.S. District Court for the District of New Jersey entered judgment against Actavis, now known as Allergan (AGN), and in favor of Supernus (SUPN) as to the '898 and '131 patents disputed in a lawsuit between the two companies. The court found against Supernus and in favor of Actavis as to the '600 patent, according to a court filing. The Patents-in-Suit relate to Supernus' Oxtellar XR drug indicated for the treatment of seizures. Shares of Supernus are up 29% in afternoon trading following the court ruling.
06:23 EDTIBM20 companies make alliance to keep down healthcare costs, WSJ says
Subscribe for More Information
February 4, 2016
15:39 EDTTOTWhite House 'clean transportation' plan proposes $10 per barrel fee on oil
Subscribe for More Information
05:45 EDTSTOStatoil reports Q4 adjusted earnings NOK 15.2B vs. NOK 26.9B last year
Statoil delivered equity production of 2,046 mboe per day in Q4. Statoil's net operating income according to IFRS for Q4 was NOK 1.7B, compared to NOK 9.0B in the same period in 2014.
February 3, 2016
09:15 EDTIBMIBM acquiring German digital agency exc.io
Subscribe for More Information
06:13 EDTAGNPfizer insists Allergan deal won't be thwarted by U.S. politicians, FT says
Pfizer (PFE) has insisted that its $160B acquisition of Allergan (AGN) will not be stifled by political opposition, amid criticism that the deal will cost the U.S. Treasury billions of dollars in future tax revenues, the Financial Times reports. Pfizer CEO Ian Read also reiterated his intention to postpone until 2018 a decision on whether to break of the combined entity into two or three smaller companies, but has said that he would be open to offers for its generics unit, the report says. Mylan (MYL) has been connected to a potential acquisition of Pfizer's generic drugs business after it failed in its attempt to buy Perrigo (PRGO) last year, the report says. Reference Link
February 2, 2016
10:59 EDTAGNPfizer CEO confident Allergan deal can close in second half
Subscribe for More Information
07:17 EDTTOTIran still struggling to finalize oil drilling contract terms, WSJ says
Iran is still having difficulty finalizing terms under which foreign energy companies can drill for oil there, the Wall Street Journal reports. Iranian oil officials canceled a conference scheduled for this month in London where new contracts for Western companies were supposed to be presented, with official blaming the cancellations on the inability to secure enough U.K. visas for the event, the report says. Another reason for the cancellation are conservative factions thinking that the contracts drawn up by president Hassan Rouhani's oil ministry are too generous to foreign entities, the report says, citing people familiar with the matter. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:54 EDTAGNPfizer expects combination with Allergan to occur in 2H16
Subscribe for More Information
06:09 EDTIBMIBM agrees to acquire Aperto, terms not disclosed
IBM announced it has signed a definitive agreement to acquire Aperto, a digital agency with headquarters in Berlin. Upon completion of this transaction, Aperto will to join the IBM Interactive Experience team, supporting IBM's growth in the largest economy in Europe. Aperto's 300-plus employees will continue to serve its roster of clients. The transaction is expected to close in Q1 and is subject to applicable regulatory review and customary closing conditions. Financial details were not disclosed.
05:33 EDTTOTTotal signs long-term agreement to supply LNG to Pertamina
Total has signed long-term liquefied natural gas, or LNG, sale and purchase agreements with state-owned Indonesian company Pertamina for the supply of LNG volumes increasing from 0.4M to 1M tonnes per year over a period of 15 years beginning 2020. Under the terms of the agreements, Total will purchase from 2020 around 0.4M tonnes per year of Pertamina's contracted LNG volumes from Corpus Christi LNG, currently under construction in the United States. In parallel, Total will supply from its global portfolio to Pertamina a volume growing over time from 0.4M to 1M tonnes per year of LNG.
February 1, 2016
13:49 EDTTOT, STOS&P cuts rating on Shell, puts several other EU oil majors on watch
Subscribe for More Information
13:25 EDTAGNEarnings Watch: Pfizer shares down approximately 12% since last earnings report
Pfizer (PFE) is scheduled to report fourth quarter earnings before the market open on Tuesday, February 2, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.57B, according to First Call. The consensus range for EPS is 49c-54c on revenue of $13.08B-$13.99B. LAST QUARTER: After completing its Hospira acquisition in early September, Pfizer reported third quarter EPS of 60c, which beat consensus estimates of 51c, on revenue of $12.1B, which was also higher than consensus estimates of $11.56B. In Q3 Operational revenue growth in in developed markets was driven primarily by the performance of several key products, including Prevnar 13 in adults, Ibrance and Eliquis -- all products that are early in their life cycles as well as from Lyrica primarily in the U.S., and the inclusion of one month of legacy Hospira U.S. operations. In emerging markets, revenues increased 5% operationally, reflecting continued strong operational growth, primarily from the Innovative Products business. Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S., Zyvox in the U.S. and Lyrica in certain developed Europe markets. With its Q3 earnings announcement the company raised its fiscal year 2015 earnings per share view to $2.16-$2.20 from $2.04-$2.10 against a raised revenue view of $47.5B-$48.5B from $46.5B-$47.5B. Commenting on the improved yearly view, the company CFO said "We raised our 2015 financial guidance for reported revenues and adjusted diluted EPS to reflect the strong performance to date of Pfizer-standalone, excluding legacy Hospira operations coupled with an improved business outlook for Pfizer-standalone for the remainder of the year.PFIZER-ALLERGAN DEAL. On November 23, Pfizer and Allergan (AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan. Pfizer at the time said it anticipates the Allergan transaction will deliver more than $2B in operational synergies over the first three years after closing. Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate of approximately 17%-18% by the first full year after the closing of the transaction. The transaction is expected to be neutral to Pfizer's Adjusted Diluted EPS in 2017, modestly accretive beginning in calendar year 2018, more than 10% accretive in 2019 with high-teens percentage accretion in 2020. STREET RESEARCH: On December 1, Barclays analyst Geoff Meacham kept an Equal Weight rating on Pfizer after assuming coverage of the name. The analyst maintained a $34 price target for shares.On November 25, SunTrust upgraded Pfizer to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap. PRICE ACTION: Shares of Pfizer are lower by approximately 12% since its last earnings report on October 27. Pfizer shares are trading over 1% lower to $29.97 in afternoon trading ahead of Tuesday morning's earnings.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use